Summary data from the U.K.’s National Joint Registry indicates that patients treated with the Conformis iTotal CR knee experienced a cumulative revision rate of 0.5% at four years vs. a 1.9% cumulative revision rate at four years, among all patients who underwent knee replacement.
The data summarized 576 iTotal procedures in 504 patients from 46 centers in the U.K. Among those treated with iTotal implants, just three (0.5%) required revision by four years.
The iTotal CR recently received a 3A rating from the U.K.’s Orthopaedic Data Evaluation Panel, reflecting strong evidence of performance over three years, including low revision rates.
Summary data from the U.K.'s National Joint Registry indicates that patients treated with the Conformis iTotal CR knee experienced a cumulative revision rate of 0.5% at four years vs. a 1.9% cumulative revision rate at four years, among all patients who underwent knee replacement.
The data summarized 576 iTotal procedures in 504 patients from...
Summary data from the U.K.’s National Joint Registry indicates that patients treated with the Conformis iTotal CR knee experienced a cumulative revision rate of 0.5% at four years vs. a 1.9% cumulative revision rate at four years, among all patients who underwent knee replacement.
The data summarized 576 iTotal procedures in 504 patients from 46 centers in the U.K. Among those treated with iTotal implants, just three (0.5%) required revision by four years.
The iTotal CR recently received a 3A rating from the U.K.’s Orthopaedic Data Evaluation Panel, reflecting strong evidence of performance over three years, including low revision rates.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more
Copy to clipboard 
